Insights from 4 Analyst Ratings on Schrodinger
Analyst Ratings Overview: Schrodinger (SDGR) received mixed ratings from four analysts, with two being somewhat bullish and two indifferent over the last quarter, reflecting a shift in sentiment compared to previous months.
Price Target Insights: Analysts have set an average 12-month price target of $23.5 for Schrodinger, down from $31.67, with estimates ranging from a low of $19.00 to a high of $30.00.
Financial Performance Metrics: Schrodinger's revenue growth rate is approximately 15.69%, but it struggles with profitability, showing a net margin of -78.84% and ROE of -12.05%, indicating challenges in cost management and equity utilization.
Debt Management Position: The company maintains a favorable debt-to-equity ratio of 0.33, suggesting a lower reliance on debt financing compared to industry averages, which may be viewed positively by investors.
Get Free Real-Time Notifications for Any Stock
Analyst Views on SDGR
About SDGR
About the author

VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.

VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Potential: The global AI medical imaging market reached $2.57 trillion in 2026, driving the AI drug discovery sector to $1.81 billion, indicating a strong shift towards AI-native diagnostic precision in healthcare.
- Increased Funding: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization activities, manufacturing scale-up, and regulatory submissions, facilitating the company's transition from development to revenue generation.
- Economic Value Proof: VentriPoint partnered with Summit Sciences to develop ROI models that demonstrate measurable returns for hospitals through process improvements and resource optimization, emphasizing the economic rationale of their technology.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, leveraging his extensive management experience in medical technology to accelerate market adoption and drive revenue growth.









